Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00004007 |
RATIONALE: Studying individuals and families at high risk for cancer may help to identify other persons at risk and identify cancer genes.
PURPOSE: This clinical trial is studying genetic and environmental factors related to cancer risk in individuals and families at high risk for cancer.
Condition | Intervention |
---|---|
Bladder Cancer Brain and Central Nervous System Tumors Chordoma Lung Cancer Non-Melanomatous Skin Cancer Retinoblastoma Sarcoma |
Procedure: comparative genomic hybridization Procedure: gene rearrangement analysis Procedure: genetic linkage analysis Procedure: laboratory biomarker analysis Procedure: mutation analysis Procedure: questionnaire administration |
Study Type: | Observational |
Official Title: | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer |
Estimated Enrollment: | 7500 |
Study Start Date: | January 1978 |
Estimated Primary Completion Date: | December 2020 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: One family member completes a family history questionnaire for verification of diagnosis and construction of a family pedigree. Individuals and families undergo clinical evaluation comprising at least a medical history, physical examination, and testing of blood specimens. Other biologic specimens may also be obtained from some individuals, and some individuals may undergo other diagnostic studies and examinations, depending on the type of familial neoplasm being studied.
If a family is already participating in the study and a specific mutation in a tumor predisposing gene predictive of disease has already been identified in the family, individuals may be eligible for genetic testing. Genes tested include RB1, APC, BRCA1/2, NF2, and VHL. Individuals under age 18 are only eligible to be tested for APC (familial adenomatous polyposis), NF2 (neurofibromatosis type 2), PTCH (nevoid basal cell carcinoma syndrome), RB1 (retinoblastoma), and VHL (von Hippel-Lindau disease).
Individuals may receive results of the genetic testing and genetic counseling is offered to all individuals who are tested.
A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
Families are followed every 1-2 years. In selected instances, individuals and families may return to the Clinical Center periodically for study-specific follow-up evaluations.
PROJECTED ACCRUAL: A total of 7,500 individuals will be accrued for this study. Substudies, involving subsets of the 7,500 individuals, are part of the overall study design.
Ages Eligible for Study: | up to 95 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
DISEASE CHARACTERISTICS:
Family or personal medical history of neoplasia of unusual type, pattern, or number
The following types of familial cancers are eligible:
The following type of familial benign neoplasm is eligible:
Known or suspected factor(s) predisposing to neoplasia, meeting 1 of the following criteria:
Environmental exposure, including:
Genetic and/or congenital factors, including:
Unusual demographic features, including:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, Maryland | |
NCI - Division of Cancer Epidemiology and Genetics | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Contact: Genetic Epidemiology Branch Referral Nurse 800-518-8474 | |
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
Bethesda, Maryland, United States, 20892-1182 | |
Contact: Patient Recruitment 888-NCI-1937 |
Study Chair: | Margaret A. Tucker, MD | NCI - Genetic Epidemiology Branch |
Study ID Numbers: | CDR0000067218, NCI-78-C-0039 |
Study First Received: | November 1, 1999 |
Last Updated: | December 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00004007 |
Health Authority: | Unspecified |
Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET) small cell lung cancer non-small cell lung cancer childhood brain tumor osteosarcoma |
basal cell carcinoma of the skin retinoblastoma adult brain tumor bladder cancer chordoma |
Retinal Neoplasms Thoracic Neoplasms Neuroectodermal Tumors, Primitive Ewing's family of tumors Malignant mesenchymal tumor Urogenital Neoplasms Central Nervous System Neoplasms Retinoblastoma Urologic Neoplasms Osteogenic sarcoma Chordoma Soft tissue sarcomas Neoplasms, Connective and Soft Tissue Ewing's sarcoma Sarcoma, Ewing's |
Respiratory Tract Diseases Urologic Diseases Lung Neoplasms Neoplasms, Germ Cell and Embryonal Neuroepithelioma Retinal Diseases Nervous System Neoplasms Bladder neoplasm Non-small cell lung cancer Cystocele Eye Neoplasms Skin Diseases Eye Diseases Urinary Bladder Diseases Urinary Bladder Neoplasms |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site |
Neoplasms, Nerve Tissue Nervous System Diseases Neoplasms, Neuroepithelial |